Viruses 2013, 5(10), 2585-2600; doi:10.3390/v5102585
Review

Foamy Virus Vectors for HIV Gene Therapy

1 Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA 2 School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA
* Author to whom correspondence should be addressed.
Received: 1 September 2013; in revised form: 10 October 2013 / Accepted: 16 October 2013 / Published: 22 October 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
PDF Full-text Download PDF Full-Text [477 KB, uploaded 22 October 2013 11:35 CEST]
Abstract: Highly active antiretroviral therapy (HAART) has vastly improved outcomes for patients infected with HIV, yet it is a lifelong regimen that is expensive and has significant side effects. Retroviral gene therapy is a promising alternative treatment for HIV/AIDS; however, inefficient gene delivery to hematopoietic stem cells (HSCs) has so far limited the efficacy of this approach. Foamy virus (FV) vectors are derived from non-pathogenic viruses that are not endemic to the human population. FV vectors have been used to deliver HIV-inhibiting transgenes to human HSCs, and they have several advantages relative to other retroviral vectors. These include an attractive safety profile, broad tropism, a large transgene capacity, and the ability to persist in quiescent cells. In addition, the titers of FV vectors are not reduced by anti-HIV transgenes that affect the production of lentivirus (LV) vectors. Thus FV vectors are very promising for anti-HIV gene therapy. This review covers the advantages of FV vectors and describes their preclinical development for anti-HIV gene therapy.
Keywords: foamy virus; lentivirus; retrovirus; vector; gene therapy; HIV

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Olszko, M.E.; Trobridge, G.D. Foamy Virus Vectors for HIV Gene Therapy. Viruses 2013, 5, 2585-2600.

AMA Style

Olszko ME, Trobridge GD. Foamy Virus Vectors for HIV Gene Therapy. Viruses. 2013; 5(10):2585-2600.

Chicago/Turabian Style

Olszko, Miles E.; Trobridge, Grant D. 2013. "Foamy Virus Vectors for HIV Gene Therapy." Viruses 5, no. 10: 2585-2600.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert